A company that truly wanted to get involved would
Post# of 15624
At some point in the future they could easily acquire it as an alliance with major institutions who would own major portions of the company by then could easily force an agreement to buy it out. They could then spin it off maintaining a majority interest, just as Roche did with Genentech a few times, and could do again.
Such a partnership would immediately have the share price well over a dollar and the company would have funding sufficient to operate for years and expand both staff and their trial efforts. I believe this is the sort of thing we may see, not a buyout.
Gary